Anti-ATP synthase autoantibodies from patients with Alzheimer's disease reduce extracellular HDL level

Journal of Alzheimer's Disease

Volumn 26, Issue 3, 2011, Pages 441-445

  Vacirca, Davide ^a   Barbati, Cristiana ^a,b   Scazzocchio, Beatrice ^a   Masella, Roberta ^a   Rosano, Giuseppe ^b   Malorni, Walter ^a,b   Ortona, Elena ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Istituto San Raffaele Dulmoisa   (Italy)

Author keywords

Alzheimer's disease; ATP synthase; autoantibodies; HDL; piceatannol

Indexed keywords

ADENOSINE DIPHOSPHATE; AUTOANTIBODY; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PICEATANNOL; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY DETECTION; ARTICLE; BIOSYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR FLUID; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; HYDROLYSIS; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR;

EID: 80053234359     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110350     Document Type: Article

References (20)

1. Qiu C, Xu W, Fratiglioni L (2010) Vascular and psychosocial factors in Alzheimer's disease: epidemiological evidence toward intervention. J Alzheimers Dis 20, 689-697.
2. Michikawa M (2003) Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J Neurosci Res 72, 141-146.
3. Merched A, Xia Y, Visvikis S, Serot JM, Siest G (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 21, 27-30.
4. Michikawa M (2004) Neurodegenerative disorders and cholesterol. Curr Alzheimer Res 1, 271-275.
5. Martinez LO, Jacquet S, Tercé F, Collet X, Perret B, Barbaras R (2004 New insight on the molecular mechanisms of highdensity lipoprotein cellular interactions. Cell Mol Life Sci 61, 2343-2360.
6. Vantourout P, Radojkovic C, Lichtenstein L, Pons V, Champagne E, MartinezLO(2010) Ecto-F1-ATPase: a moonlighting protein complex and an unexpected apoA-I receptor. World J Gastroenterol 16, 5925-5935.
7. Vacirca D, Delunardo F, Matarrese P, Colasanti T, Margutti P, Siracusano A, Pontecorvo S, Capozzi A, Sorice M, Francia A, Malorni W, Ortona E (2010) Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimer's disease. Neurobiol Aging, doi:10.1016/j.neurobiolaging,2010.05. 013
8. Margutti P, Matarrese P, Conti F, Colasanti T, Delunardo F, Capozzi A, Garofalo T, Profumo E, Riganò R, Siracusano A, Alessandri C, Salvati B, Valesini G, MalorniW, Sorice M, Ortona E (2008) Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis. Blood 111, 4559-4570.
9. Yamamoto K, Shimizu N, Obi S, Kumagaya S, Taketani Y, Kamiya A, Ando J (2007) Involvement of cell surface ATP synthase in flow-induced ATP release by vascular endothelial cells. Am J Physiol Heart Circ Physiol 293, H1646-H1653.
10. Burwick NR, Wahl ML, Fang J, Zhong Z, Moser TL, Li B, Capaldi RA, Kenan DJ, Pizzo SV (2005) An Inhibitor of the F1 subunit of ATP synthase (IF1) modulates the activity of angiostatin on the endothelial cell surface. J Biol Chem 280, 1740-1745.
11. Teupser D, Thiery J,Walli AK, SeidelD(1996) Determination of LDL- and scavenger-receptor activity in adherent and nonadherent cultured cells with a new single-step fluorometric assay. Biochim Biophys Acta 1303, 193-198.
12. Chung BH, Segrest JP, Ray MJ (1986) Single vertical spin density gradient ultracentrifugation. Methods Enzymol 128, 181-209.
13. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezón E, Champagne E, Pineau T, Georgeaud V, Walker JE, Tercé F, Collet X, Perret B, Barbaras R (2003) Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421, 75-79.
14. Bastianetto S, Dumont Y, Han Y, Quirion R (2009) Comparative neuroprotective properties of stilbene and catechin analogs: action via a plasma membrane receptor site? CNS Neurosci Ther 15, 76-83.
15. Reitz C, Tang MX, Luchsinger J, Mayeux R (2004) Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 61, 705-714.
16. Reitz C, Tang MX, Schupf N, Manly J, Mayeux R, Luchsinger JA (2010) Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol 67, 1491-1497.
17. Eckert GP, Kirsch C, Leutz S,Wood WG,Müller WE. (2003) Cholesterol modulates amyloid beta-peptide's membrane interactions. Pharmacopsychiatry 36, Suppl 2: S136-S43.
18. Koudinov AR, Koudinova NV (2001) Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 15, 1858-1860.
19. Richard T, Pawlus AD, Iglésias ML, Pedrot E,Waffo-Teguo P, Mérillon JM, Monti JP (2011) Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci 1215, 103-108.
20. Stampfer MJ, Kang JH, Chen J, Cherry R, Grodstein F (2005) Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med 352, 245-253.